Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

University of Queensland researchers have discovered immunotherapy, when used to treat people with advanced cancers, also ...

A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for an uncommon skin cancer called cutaneous squamous cell carcinoma (CSCC), but Sanofi and Regeneron are ...

To fill this knowledge gap, Ikeda and colleagues obtained tumour-infiltrating T cells and cancer cells from human tumours that were surgically removed and sequenced the mitochondrial DNA (mtDNA ...

how effective the treatment is and if there are any side effects – for patients with localised skin cancer. But the next phase of research is not only about testing whether Flash works in people.

Medicare covers inpatient and outpatient care for skin cancer. People with Original Medicare parts A and B or Medicare Advantage plans can expect extensive coverage, but they will likely have out ...